From Nasdaq: 2025-04-30 22:34:00

Pfizer stock (NYSE: PFE) reported Q1 results with revenue at $13.7 billion and adjusted earnings of $0.92 per share, missing and exceeding estimates, respectively. The company reaffirmed its full-year guidance. PFE stock has underperformed the S&P 500 this year due to negative developments like discontinuation of treatments. Consider the High Quality portfolio for potential upside.

In Q1, Pfizer saw an 8% y-o-y revenue decline to $13.7 billion. Vyndaqel sales surged, Paxlovid sales dropped, and Comirnaty generated $565 million, up from $354 million in the previous year. Pfizer’s adjusted net income margin improved to 38.2%, leading to a 12% y-o-y rise in earnings to $0.92 per share.

Pfizer maintains its 2025 outlook with sales between $61 billion and $64 billion and adjusted earnings per share at $2.80 to $3.00. The company aims for cost-savings of $7.7 billion by year-end. Despite a mixed Q1, PFE stock hasn’t seen significant changes post-results. The High Quality Portfolio has outperformed the S&P 500 over the past four years.

While PFE stock may be undervalued, monitor Pfizer’s performance against peers in the industry. Consider investing in Market-Beating Portfolios with Trefis for potential returns. Check out Trefis Price Estimates for more insights.



Read more at Nasdaq: What’s Next For Pfizer Stock After A Mixed Q1?